Tranexamic Acid 氨甲环酸

CAS 1197-18-8 MFCD00001466

化学结构图

1197-18-8
SMILES: NCC1CCC(C(=O)O)CC1

化学属性

Mol. FormulaC8H15NO2
Mol. Weight157.21
Melting Point>300°C
TSCANo
Density1.096
Solubility1G/6ML
Boiling Point300.2°C at 760 mmHg
Flash Point135.4°C

别名和识别编码

Chemical Nametrans-4-(Aminomethyl)cyclohexanecarboxylic acid
MDL NumberMFCD00001466
CAS Number1197-18-8
Synonym Tranexamic acid {LY} Tranexamic acid {} {LY} Tranexamic acid {} {} {LY} Tranexamic acid {} {} {} {LY} Tranexamic acid {} {} {} {} {LY} Tranexamic acid {} {} {} {} {} {LY} Tranexamic acid {} {} {} {} {} {} {LY} Tranexamic acid {} {} {} {} {} {} {} {LY} Tranexamic acid {} {} {} {} {} {} {} {} {LY} Tranexamic acid {} {} {} {} {} {} {} {} {} {LY} Tranexamic acid {} {} {} {} {} {} {} {} {} {} {LY} Tranexamic acid {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {LY} Tranexamic acid {} {} {} {} {} {} {} {} {} {} {} {} { {} {} {} {} {} {} {} {} {} {} {} {} {LY} Tranexamic acid {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {LY} Tranexamic acid {} {} {} {} {} {} {} {} {} {} {} {} {} {} { {} {} {} {} {} {} {} {} {} {} {} {} {} {} {LY} Tranexamic acid {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {LY} Tranexamic acid {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {}
PubChem Substance ID5526
Beilstein Registry Number2207452
EC Number214-818-2
Merck Number9569
Reaxys-RN2207452
Chemical Name Translation氨甲环酸
InChIKeyGYDJEQRTZSCIOI-LJGSYFOKSA-N
Alfabeta NameAMINOMETHYLCYCLOHEXANECARBOXYLICACID TRANS4(())--
Wiswesser Line NotationL6TJ AVQ D1Z -T
LabNetwork Molecule IDLN00009629
InChIInChI=1S/C8H15NO2/c9-5-6-1-3-7(4-2-6)8(10)11/h6-7H,1-5,9H2,(H,10,11)
Canonical SMILESO=C([C@H]1CC[C@H](CN)CC1)O
信息真实价格透明    资金保障    专业采购外包团队在线服务   
信息真实价格透明    资金保障    专业采购外包团队在线服务   
品牌质保精细包装    现货库存    一流品牌服务   

分类

  • {SNA} Analytical Standards, Analytical/Chromatography, Chromatography, Pharmaceutical Standards, Pharmacopeia Standards, USP Standar
  • {SNA} Analytical Standards, Chromatography, EP Standards, EP Standards S - T, Pharmaceutical Standards, Pharmacopeia Standards, 分析/色谱
  • {SNA}
  • {SNA} Analytical Standards, Pharmacopeia Metrological Institutes Standards, USP Standards, USP Standards S - T, 分析/色谱
  • {SNA} Analytical Standards, EP Standards, EP Standards S - T, Pharmacopeia & Metrological Institutes Standards, 分析/色谱
  • {SNA} Analytical Standards, Pharmacopeia & Metrological Institutes Standards, USP Standards,

安全信息

RTECSGU8400000
GHS Symbol
Precautionary statements
  • P280 Wear protective gloves/protective clothing/eye protection/face protection. 戴防护手套/防护服/眼睛的保护物/面部保护物。
  • P362 Take off contaminated clothing and wash before reuse. 脱掉污染的衣服,清洗后方可重新使用
  • P264 Wash hands thoroughly after handling. 处理后要彻底洗净双手。
  • P261 Avoid breathing dust/fume/gas/mist/vapours/spray. 避免吸入粉尘/烟/气体/烟雾/蒸汽/喷雾。
  • P305+P351+P338
  • P305+P351+P338+P337+P313
Hazard statements
  • H315 Causes skin irritation 会刺激皮肤
  • H319 Causes serious eye irritation 严重刺激眼睛
  • H335 May cause respiratory irritation 可能导致呼吸道刺激
WGK Germany2
Personal Protective Equipment dust mask type N95 (US), Eyeshields, Gloves
Signal word
Safety Statements
  • S26 In case of contact with eyes, rinse immediately with plenty of water and seek medical advice 眼睛接触后,立即用大量水冲洗并征求医生意见;
  • S36 Wear suitable protective clothing 穿戴适当的防护服;
Risk Statements
  • R36/37/38 Irritating to eyes, respiratory system and skin 对眼睛、呼吸系统和皮肤有刺激性
Hazard Codes Xi
Storage condition 2-8°C {LY} 2-8°C Store at 0°C {} {LY} 2-8°C {} {} {LY} 2-8°C {} {} {} {LY} 2-8°C {} {} {} {} {LY} 2-8°C {} {} {} {} {} {LY} 2-8°C {} {} {} {} {} {} {LY} 2-8°C {} {} {} {} {} {} {} {LY} 2-8°C {} {} {} {} {} {} {} {} {LY} 2-8°C {} {} {} {} {} {} {} {} {} {LY} 2-8°C {} {} {} {} {} {} {} {} {} {} {LY} 2-8°C {} {} {} {} {} {} {} {} {} {} {} {LY} 2-8°C {} {} {} {} {} {} {} {} {} {} {} {} {LY} 2-8°C {} {} {} {} {} {} {} {} {} {} {} {} {} {LY} 2-8°C {} {} {} {} {} {} {} {} {} {} {} {} {} {} {LY} 2-8°C {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {LY} 2-8°C {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {LY} 2-8°C {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {LY} 2-8°C {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {LY} 2-8°C {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {LY} 2-8°C {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {LY} 2-8°C {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {LY} 2-8°C
TYPE OF TEST            : LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE       : Oral
SPECIES OBSERVED        : Bird - chicken
DOSE/DURATION           : >10 gm/kg
TOXIC EFFECTS :
   Details of toxic effects not reported other than lethal dose value
REFERENCE :
   OYYAA2 Oyo Yakuri.  Pharmacometrics.  (Oyo Yakuri Kenkyukai, CPO Box 180,
   Sendai 980-91, Japan) V.1-    1967-  Volume(issue)/page/year: 5,389,1971

TYPE OF TEST            : LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE       : Subcutaneous
SPECIES OBSERVED        : Rodent - mouse
DOSE/DURATION           : 5310 mg/kg
TOXIC EFFECTS :
   Details of toxic effects not reported other than lethal dose value
REFERENCE :
   NIIRDN Drugs in Japan (Ethical Drugs).  (Yakugyo Jiho Co., Ltd., Tokyo,
   Japan)  Volume(issue)/page/year: 6,512,1982

TYPE OF TEST            : LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE       : Intravenous
SPECIES OBSERVED        : Rodent - rat
DOSE/DURATION           : 1200 mg/kg
TOXIC EFFECTS :
   Details of toxic effects not reported other than letha

TYPE OF TEST            : LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE       : Intraperitoneal
SPECIES OBSERVED        : Rodent - mouse
DOSE/DURATION           : 4200 mg/kg
TOXIC EFFECTS :
   Details of toxic effects not reported other than lethal dose value
REFERENCE :
   85IRAK "Modern Pharmaceuticals of Japan, V," Tokyo, Japan Pharmaceutical,
   Medical and Dental Supply Exporters' Assoc.,  1975 Volume(issue)/page/year:
   -,108,1975

TYPE OF TEST            : LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE       : Intravenous
SPECIES OBSERVED        : Mammal - dog
DOSE/DURATION           : 1110 mg/kg
TOXIC EFFECTS :
   Details of toxic effects not reported other than lethal dose value
REFERENCE :
   NIIRDN Drugs in Japan (Ethical Drugs).  (Yakugyo Jiho Co., Ltd., Tokyo,
   Japan)  Volume(issue)

TYPE OF TEST            : TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE       : Oral
SPECIES OBSERVED        : Rodent - rat
DOSE                    : 305 gm/kg
SEX/DURATION            : female 40 day(s) pre-mating
                          female 1-21 day(s) after conception
TOXIC EFFECTS :
   Reproductive - Fertility - female fertility index (e.g. # females pregnant
   per # sperm positive females; # females pregnant per # females mated)
REFERENCE :
   APTOA6 Acta Pharmacologica et Toxicologica.  (Copenhagen, Denmark)  V.1-59,
   1945-86.  For publisher information, see PHTOEH  Volume(issue)/page/year:
   22,340,1965

TYPE OF TEST            : TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE       : Oral
SPECIES OBSERVED        : Rodent - mouse
DOSE                    : 9 mg/kg
SEX/DURATION            : female 7-12 day(s) after conception
TOXIC EFFECTS :
   Reproductive - Effects on Newborn - weaning or lactation index (e.g., #
   alive at weaning per # alive at day 4)
REFERENCE :
   OYYAA2 Oyo Yakuri.  Pharmacometrics.  (Oyo Yakuri Kenkyukai, CPO Box 180,
   Sendai 980-91, Japan) V.1-    1967-  Volume(issue)/page/year: 5,415,1971

TYPE OF TEST            : TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE       : Oral
SPECIES OBSERVED        : Rodent - rat
DOSE                    : 9 mg/kg
SEX/DURATION            : female 9-14 day(s) after conception
TOXIC EFFECTS :
   Reproductive - Effects on Embryo or Fetus - fetotoxicity (except death,
   e.g., stunted fetus)
REFERENCE :
   OYYAA2 Oyo Yakuri.  Pharmacometrics.  (Oyo Yakuri Kenkyukai, CPO Box 180,
   Sendai 980-91, Japan) V.1-    1967-  Volume(issue)/page/year: 5,415,1971

其他信息

  • 不良反应与注意事项:服用氨甲环酸的不良反应较氨基己酸为少。可能出现头痛、头晕、恶心、腹泻、呕吐、胸闷、嗜睡等症状,停药后即可逐渐消失,偶有药物过量所致颅内血栓形成和出血,较少见的有经期不适(经期血液凝固所致)。由于本品可进入脑脊液,注射后可有视力模糊、头痛、头晕、疲乏等中枢神经系统症状,特别与注射速度有关,但很少见。必须持续应用本品较久者,应作眼科检查监护(例如视力测验、视觉、视野和眼底)。对于有血栓形成倾向(如急性心肌梗死)宜慎用;肾功能不全、术后有血尿者慎用;弥散性血管内凝血所致的继发性高纤溶状态,在未肝素化前,慎用本品;如与其他凝血因子(如因子Ⅸ)等合用,应警惕血栓形成。氨甲环酸与青霉素或尿激酶等溶栓剂有配伍禁忌;口服避孕药、雌激素或凝血酶原复合物浓缩剂与本品合用,有增加血栓形成的危险。
  • 氨甲环酸价格(试剂级):更新日期 产品编号 产品名称 包装 价格 2014/06/02 A0236 反-4-(氨甲基)环己烷甲酸 trans-4-(Aminomethyl)cyclohexanecarboxylic Acid 5G 100元 2014/06/02 A0236 反-4-(氨甲基)环己烷甲酸 trans-4-(Aminomethyl)cyclohexanecarboxylic Acid 25G 350元 2010/06/21 228040500 氨甲环酸 trans-4-(Aminomethyl)cyclohexanecarboxylic acid 98+% 50 GR 1496元
  • 促凝血及止血药物:氨甲环酸为氨甲苯酸的衍生物,是一种抗纤溶的止血药物,止血机制与氨基己酸、氨甲苯酸相同,但作用更强,强度是氨基己酸的7~10倍、氨甲苯酸的2倍,而毒性相近。 氨甲环酸化学结构与赖氨酸相似,能竞争性阻抑纤溶酶原在纤维蛋白上吸附,防止其激活,保护纤维蛋白不被纤溶酶所降解和溶解,最终达到止血效果。适用于治疗急性或慢性、局限性或全身性原发性纤维蛋白溶解亢进所致的各种出血,如产科出血,肾出血、前列腺肥大出血、血友病、肺结核喀血、胃出血、肝、肺、脾等内脏手术后的出血等;也可用于手术时异常出血等。 临床上氨甲环酸对虫咬症、湿疹皮炎、单纯性紫癜、慢性荨麻疹、人工性荨麻疹、中毒疹和药疹等效果显著,对红皮病、硬皮病、SLE、多形红斑、带状疱疹和斑秃亦有一定疗效,对遗传性血管性水肿疗效亦较好。治疗黄褐斑一般用药3周左右见效,5周显效, 60 d一疗程。每次口服0.25~0.5g,一日3~ 4次。少数患者可发生恶心、疲乏、瘙痒、腹部不适和腹泻等副作用,停药后症状即消失。 以上信息由Chemicalbook的晓楠编辑整理。
  • 图谱信息:氨甲环酸(1197-18-8)红外图谱(IR2) 氨甲环酸(1197-18-8)红外图谱(IR1) 氨甲环酸(1197-18-8)质谱(MS) 氨甲环酸(1197-18-8)Raman光谱
  • MOL 文件:1197-18-8.mol
  • 用途:止血药,对创伤性出血效果显著,术前预防性用药可减少手术出血。
  • RTECS号:GU8400000

系列性分类


相关产品推荐